Oxcarbazepine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Oxcarbazepine: From Epilepsy to Visual Epilepsy
One-Sentence Summary
Oxcarbazepine is a sodium-channel-blocking antiepileptic drug (AED) established for the treatment of partial-onset (focal) epilepsy and trigeminal neuralgia. The TxGNN model predicts it may also be effective for Visual Epilepsy (a reflex epilepsy subtype triggered by visual stimuli), with 1 clinical trial and 19 publications currently retrieved — though none of them specifically studied this seizure subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (partial-onset / focal seizures) — established international use; no local registration data available |
| Predicted New Indication | Visual Epilepsy |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal DrugBank mechanism-of-action data for Oxcarbazepine is not available in this evidence pack (flagged as a data gap). Based on well-established pharmacology, however, Oxcarbazepine is a voltage-gated sodium channel blocker in the AED class, structurally the 10-keto analogue of carbamazepine. It stabilizes hyperexcitable neuronal membranes and limits repetitive high-frequency firing — a mechanism with proven clinical efficacy in partial-onset and generalized tonic-clonic seizures.
Visual epilepsy is a form of reflex epilepsy in which seizures are triggered by visual stimuli (e.g., flickering light or patterns). Because the underlying pathology — cortical hyperexcitability and abnormal synchronized discharge — is shared across most epilepsy subtypes, sodium-channel-blocking AEDs such as oxcarbazepine are mechanistically plausible for reflex/visually-induced seizures as well.
That said, none of the retrieved evidence is specific to visual epilepsy. The single clinical trial (NCT00855738) evaluated several AEDs, including oxcarbazepine, as first-choice bitherapy in general focal epilepsy without isolating the visually-triggered subtype (relevance graded “C” — not specific). The 19 retrieved publications are general AED/epilepsy reviews and pharmacology papers rather than visual-epilepsy-specific studies. This prediction should therefore be read as a mechanism-based extrapolation from the general epilepsy indication, not a validated subtype-specific signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00855738 | Phase 4 | Completed | 111 | Observational study assessing new AEDs (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate) as first-choice bitherapy in focal epilepsy; not specific to visually-induced seizures |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35429132 | 2022 | RCT | CNS Neurosci Ther | Multicenter randomized study: oxcarbazepine monotherapy showed comparable efficacy to levetiracetam in newly diagnosed focal epilepsy |
| 27845825 | 2016 | Systematic Review (Cochrane, withdrawn) | Cochrane Database Syst Rev | Reviewed oxcarbazepine as add-on therapy for drug-resistant partial epilepsy |
| 33334546 | 2020 | Review | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management relative to newer AEDs |
| 35380580 | 2022 | Review | JAMA | Overview of antiseizure medications for adults with epilepsy, including oxcarbazepine |
| 10530693 | 1999 | Review | Epilepsia | Early review of oxcarbazepine as a broad-spectrum AED, its pharmacology and clinical role |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Oxcarbazepine efficacy in partial seizures, trigeminal neuralgia, and neuropathic pain |
| 1379159 | 1992 | Review | Drugs | Pharmacology and therapeutic potential of oxcarbazepine in epilepsy, trigeminal neuralgia, and affective disorders |
| 26844734 | 2016 | Review | Continuum (Minneap Minn) | Comprehensive review of AEDs including oxcarbazepine pharmacokinetics and modes of use |
| 39899099 | 2025 | Review | Continuum (Minneap Minn) | Updated overview of antiseizure medications available to neurologists |
| 22091603 | 2012 | Case series | Epilepsia | Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in epilepsy patients |
None of the above studies specifically investigate visual/photosensitive epilepsy; all support the general epilepsy indication.
India Market Information
Oxcarbazepine is currently not marketed in India — 0 registrations are on record, and no license or approved-indication data is available.
Safety Considerations
- Drug Interactions: 248 total interactions recorded (DDInter). All retrieved entries are rated Moderate severity. Representative interacting drugs include corticosteroids (Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone), vitamin D analogs (Cholecalciferol, Calcifediol, Calcitriol), antidiabetics (Pioglitazone, Chlorpropamide, Saxagliptin, Linagliptin), opioids/GI agents (Morphine, Difenoxin, Diphenoxylate, Dronabinol), proton pump inhibitors (Omeprazole, Dexlansoprazole), the macrolide Clarithromycin, the antiemetic Aprepitant, and the enzyme substrate Eliglustat.
Detailed prescribing warnings and contraindications (e.g., from a local product label) are not yet available for this candidate — this is flagged as a Blocking data gap (see Next Steps).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction score is high, but the supporting evidence base is entirely non-specific — the single clinical trial and all 19 publications describe general AED efficacy in epilepsy rather than visual/photosensitive epilepsy specifically. At Evidence Level L4, this remains a mechanism-based hypothesis rather than a clinically substantiated repurposing signal.
To proceed, the following is needed:
- Local prescribing label / warnings and contraindications (currently a Blocking data gap — required before any S1 safety screening)
- Formal DrugBank MOA confirmation (currently a High-severity data gap)
- Case reports, case series, or trials specifically addressing oxcarbazepine in visually-induced or other reflex epilepsy subtypes
- Confirmation of local market/registration pathway, since the drug is not currently marketed in India
Appendix: Other Predicted Indications in This Evidence Pack
This evidence pack contains 10 TxGNN-predicted indications for Oxcarbazepine. Ranked by evidence quality rather than raw TxGNN score, status epilepticus stands out as the strongest candidate and may warrant its own dedicated evaluation:
| Disease | TxGNN Score | Evidence Level | Recommendation | Note | |—|—|—|—|—| | Status Epilepticus | 99.87% | L3 | Proceed with Guardrails | Case series specifically on oxcarbazepine in refractory status epilepticus; mechanistically strong but no IV formulation limits acute use | | Visual Epilepsy (this report) | 99.95% | L4 | Hold | High score but no subtype-specific evidence | | Thinking Seizures | 99.89% | L4 | Hold (Research Question) | General AED/MES-model evidence only | | Audiogenic Seizures | 99.89% | L4 | Hold | Evidence covers other reflex-epilepsy subtypes (hot water, musicogenic), not audiogenic specifically | | Reading Seizures | 99.84% | L4 | Hold | Same pattern — general reflex-epilepsy literature, not disease-specific | | Restless Legs Syndrome | 99.89% | L4 | Hold (Research Question) | Weak mechanistic link (RLS driven by dopaminergic/iron pathways, not sodium channels); only case reports | | Eating Seizures | 99.89% | L5 | Hold | No relevant literature retrieved | | Orgasm-Induced Seizures | 99.89% | L5 | Hold | No evidence retrieved — score only | | Startle Epilepsy | 99.89% | L5 | Hold | No evidence retrieved — score only | | Micturition-Induced Seizures | 99.89% | pending | pending | Scoring not yet completed |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.